Slide 1: Q2 2025 Financial Results
Stevanato Group Q2 2025 Financial Results August 5, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Stevanato Group Q2 2025 Financial Results Earnings Call
Stevanato Group Q2 2025 Financial Results Earnings Call Franco Marco Lisa Stevanato Dal Lago Miles Chairman & CEO CFO CCO and IR Q2 2025 Financial Results 3
Slide 4: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q2 2025 Financial Results
Slide 5: Delivered Top-line Growth, Increased Mix of HVS, and Expanded Margins
Delivered Top-line Growth, Increased Mix of HVS, and Expanded Margins Q2 2025: Revenue grew +8% yoy, led by strong performance in the BDS Segment (+10% yoy) that offset a slight revenue decline in the Engineering Segment (-2% yoy) Strong performance in the BDS Segment driven by growth in Soft margin
Slide 6: Demand-Driven Capacity Expansion Projects Update
Demand-Driven Capacity Expansion Projects Update Fishers (IN), U.S. Latina, Italy Supporting U.S. customers across the full value chain, Diversifying EMEA footprint with expanding capacity strategically focused to meet demand for biologics for PFS and EZ-fill® cartridges to satisfy market demand • I
Slide 7: Capital Investments Meet Rising Demand Amid The Growth In Biologics
Capital Investments Meet Rising Demand Amid The Growth In Biologics Share of BDS Revenue from Biologics Biologics present large set of opportunities – beyond GLPs – driving demand for our broad HVS portfolio: (% of BDS Revenue excl. Covid-19) • High demand for Alba® PFS (highest performance PFS in o
Slide 8: Marco Dal Lago
x Marco Dal Lago Chief Financial Officer Q2 2025 Financial Results
Slide 9: Q2 2025: Financial Highlights
Q2 2025: Financial Highlights Q2 2025: Revenue Q2 2025: Margins (€ Million) HVS non-HVS • Gross profit margin increased 210 bps to 28.1% +8% − Strong performance in the BDS Segment driven by: 260 280 ▪ (i) financial improvements from Latina and Fishers (sites remain margin-dilutive, but gaining oper
Slide 10: Q2 2025: Segment Trends
Q2 2025: Segment Trends Biopharmaceutical and Diagnostic Solutions (BDS) Segment Revenue increased 10% (12% at cc), driven by solid growth in HVS, and other containment and delivery solutions. Vial demand is stabilizing. REVENUE 222 244 • Revenue from HVS grew 13% to €116.8 million, or approx. 48% o
Slide 11: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items At Quarter Ended June 30, 2025 In July, announced financing agreements totaling €200M Funds will support: € 94.2M € 312.4M Total Cash and Cash Net Debt* • PFS capacity and future capacity for Equivalents RTU cartridges at our Latina facility • Scale-up operations in
Slide 12: Maintaining Guidance Despite Higher FX Rates and Tariffs Headwinds
Maintaining Guidance Despite Higher FX Rates and Tariffs Headwinds FY 2025 Guidance FY25 Guidance Assumptions New Previous Revenue € 1.160B - € 1.190B BDS Segment yoy growth HSD MSD to HSD ENG Segment yoy performance LDD decrease flat to LSD growth Implied Revenue Growth 5% to 8% HVS share 40% to 42
Slide 13: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q2 2025 Financial Results
Slide 14: Continue to See Sustained Momentum Driven by Healthy Market Demand and Rise in Biologics
Continue to See Sustained Momentum Driven by Healthy Market Demand and Rise in Biologics, Positioning Us Well for Long-term Profitable Growth • As we advance our multi-year investments and optimization plan, we are focused on: (i) disciplined execution, (ii) industry-leading innovation, and (iii) co
Slide 15: Thank You
Stevanato Group Q2 2025 Financial Results Thank You
Slide 16: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP f
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of Revenue to Constant Currency Revenue Reconciliation of EBITDA (Amounts in € millions) (Amounts in € millions) Biopharmaceutical For the three months For the six months Change Change and ended June 30, ended June 30, Diagnostic 202
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) Operating Income Diluted EPS Operating Income Diluted EPS Three months ended June 30, 2025 EB
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions) As of June 30, As of December 2025 31, 2024 - Goodwill and intangible assets 83.5 83.6 - Right of use assets 13.4 15.7 - Property, plant and equipment 1,280.3 1,248.4 - Financial assets - investments FVTPL 0
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) CAPEX Net (Debt) / Net Cash (Amounts in € millions) (Amounts in € millions) For the three months For the six months As of December Change Change As of June 30, ended June 30, ended June 30, 31, 2025 2024 € 2025 2024 € 2025 2024 Addition to Property
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2025 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) Operating Diluted EPS Revenue EBITDA Net Profit Profit (EUR cents) 1,160.0- Reported 1,190.0 280